



The role of estrogen in circular RNA and metabolomics in a *Neisseria gonorrhoeae* infection model

Guiyue Cai^{1,2#}, Jin Long^{3#}, Huizhi Yang⁴, Jiahao Xie², Ruitao Zou^{2#}, Chunchan Zheng¹, Xiaoxuan Chen², Shuang Liu¹, Rongyi Chen¹

¹Dermatology Department, Dermatology Hospital, Southern Medical University, Guangzhou, China; ²Clinical School, Guangdong Medical University, Zhanjiang, China; ³Shanghai Biotree Metabolomics Technology Research Center, Shanghai, China; ⁴Dermatology Department, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Contributions: (I) Conception and design: R Chen; (II) Administrative support: S Liu; (III) Provision of study materials or patients: G Cai, H Yang, J Xie; (IV) Collection and assembly of data: C Zheng, R Zou; (V) Data analysis and interpretation: J Long, X Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Rongyi Chen. Dermatology Hospital, Southern Medical University, Guangzhou 510091, China. Email: rongyichen@163.com; Shuang Liu. Dermatology Hospital, Southern Medical University, Guangzhou 510091, China. Email: 408108382@qq.com.

Background: Previous study shows that estrogen exerts both immunosuppressive and immunostimulative effects.

Methods: In this study, estrogen was added to a *Neisseria gonorrhoeae* infection model, and transcriptome sequencing and metabolomics studies were performed to clarify the changes in circular RNA (circRNA) and metabolic pathways regulated by the addition of estrogen.

Results: The results showed that following the addition of estrogen to the gonococcal infection model, the expression of circRNAs was up-regulated and the expression of circRNAs was down-regulated. In the metabolic group, it was found that after the addition of estrogen, the expression of nine metabolites was down-regulated and 61 metabolites were up-regulated. Furthermore, through network interaction analysis of differentially-expressed circRNAs and differentially-expressed metabolites, we found that the top 10 significantly related metabolites and circRNA were *2-Epoxybutane/novel_circ_0024520*; *1,2-Epoxybutane/novel_circ_0061793*; *2-Imino-4-methylpiperidine/novel_circ_0012178*; *2-Imino-4-methylpiperidine/novel_circ_0056959*; *Acetone oxime/novel_circ_0012178*; *Adifoline/novel_circ_0012178*; *CARBETAPENTANE/novel_circ_0054387*; *CARBETAPENTANE/novel_circ_0056959*; *deoxy-PF1140/mmu_circ_0000397*; and *Methyl (2E,6Z)-dodecadienoate/novel_circ_0012178*. Among these, *CARBETAPENTANE/novel_circ_0054387* and *CARBETAPENTANE/novel_circ_0056959* were positively correlated, while the remaining metabolites were negatively correlated.

Conclusions: In this study, high-throughput sequencing and metabolomics mass spectrum were applied to screen the differentially-expressed circRNAs and metabolites regulated by estrogen, which will help to provide new research ideas and indicators for asymptomatic infections in women, and can be meaningful for the relevant study in the future.

Keywords: Estrogen; *Neisseria gonorrhoeae*; circular RNA (circRNA); transcriptome sequencing; metabolic group

Submitted Feb 17, 2022. Accepted for publication Sep 13, 2022.

doi: 10.21037/atm-22-3127

View this article at: <https://dx.doi.org/10.21037/atm-22-3127>

Introduction

Estrogen is a fat-soluble steroid hormone mainly composed of estradiol, estrone, and the metabolite, estriol, which is mainly secreted by the ovary (1). The secretion of estrogen determines menstrual cycle changes, and acts to produce and maintain secondary sexual characteristics in women (2). However, recent studies have shown that it also plays a role in immune regulation (3). It has been found that estradiol affects the function of polymorphonuclear leukocytes in clearing *Neisseria gonorrhoeae* (4). Moreover, it has been demonstrated that leukocyte infiltration in the abdominal cavity decreases significantly following intraperitoneal injection of *Neisseria gonorrhoeae* in mice treated with estradiol, which may be due to the monocyte chemotaxis-inhibiting effect of estradiol in mice with gonococcal infection (5). The aforementioned experimental results suggest that increased estrogen reduces the number of neutrophils in reproductive tract secretion, indicating that estrogen can inhibit the occurrence of inflammation to a certain extent.

Estradiol inhibits the messenger RNA (mRNA) expression of interleukin 6 (IL-6), interleukin 8 (IL-8), and NLRP3 in monocytes of HeLa cells infected with *Neisseria gonorrhoeae*, suggesting that estrogen might reduce the body's response to infection by inhibiting the expression of some chemokines and inflammation-related genes (6-8). At present, some researchers have successfully established an experimental infection model of estrogen-dependent *Neisseria gonorrhoeae*, which further illustrates that estrogen can inhibit immunity, thereby increasing the likelihood of *Neisseria gonorrhoeae* infection (9). Among women infected with *Neisseria gonorrhoeae*, 30–50% are asymptomatic; however, whether estradiol inhibits the expression of inflammatory factors requires further study.

Circular RNA (circRNA) is a closed circular non-coding RNA-regulated gene expression formed by covalent bonds (10). CircRNA molecules have a closed ring structure and are not affected by RNA exonuclease, leading to a stable existence *in vivo*. CircRNA molecules are also rich in microRNA (miRNA) binding sites, which act as a miRNA sponge, participate in the occurrence and development of a variety of diseases, and are expected to become disease biomarkers (11). CircRNA, as a miRNA sponge, may alter the expression level of miRNA target genes by blocking the inhibition of miRNA on its target genes, and is involved in regulating the immune and inflammatory responses of allergic diseases at the post-transcriptional level, thereby

manipulating the occurrence and progression of various inflammatory diseases (12). However, the anti-infection immunity regulation of circRNAs has not yet been fully elucidated.

There is a specific relationship between estrogen and circRNAs, which manifests mainly via the role of circRNAs as a molecular sponge in affecting estrogen decrease, or to alter the expression of related circRNAs when the estrogen receptor is affected. However, issues such as whether there is a similar phenomenon in infection immunity and what kind of circRNA regulation of estradiol affects anti-infective immunity require further exploration. In order to further analyze estrogen regulation of circRNA and metabolism, we detected differentially-expressed circRNAs and metabolites by transcriptome sequencing and LC-MS (liquid chromatography mass spectrometry) in a *Neisseria gonorrhoeae* infection model, and the regulatory network was also analyzed. By discussing the interactions between estrogen, circRNAs, and metabolites, studying the relationship between pathogen and host, and comprehensively revealing the regulatory mechanism of estrogen on *Neisseria gonorrhoeae* infection, this study will be hugely important in the screening of anti-infection biomarkers as well as research into asymptomatic infection in female mucosa. We present the following article in accordance with the MDAR reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-3127/rc>).

Methods

Sample information

Mouse monocytes were purchased from the American Tissue Culture Collection (ATCC). Monocytes were cultured in Roswell Park Memorial Institute 1640 (RPMI 1640) medium containing 10% fetal bovine serum (FBS) in 5% CO₂ (carbon dioxide) incubator at 37 °C. The monocytes were used in the experiment when they were in the logarithmic growth phase. The cell fluid was changed every 2 days, and the cell morphology, adhesion, and growth were observed before the fluid change. When the cells were covered and adhered to the wall intact, the cells were sub-cultured, digested by 0.25 g/L trypsin Ethylenediaminetetraacetic acid (EDTA), and the cell concentration was adjusted to 2×10⁶/L. Each 5 mL bottle was inoculated into a 100 mL cell culture flask. After the cells were fused for 80%, they were divided into four groups:

a blank control group (cultured with RPMI 1640 medium containing 10% FBS for 24 hours), an estrogen group (treated with 10^{-8} mol/L estradiol for 24 hours), a gonococcal disease group (treated with 2×10^7 cfu/mL *Neisseria gonorrhoeae* suspension for 24 hours), and a gonococcal disease + estrogen treatment group (treated with 10^{-8} mol/L estradiol for 2 hours, and then treated with 2×10^7 cfu/mL gonococci for 24 hours).

RNA extraction and quality control

Total RNA was extracted using a TRIzol kit, and the RNA concentration of each sample was measured by Nano Drop. The absorbance (Optical Density OD_{260/280}) was used as the RNA purity index. The Rib-Zero ribosomal RNA (rRNA) Removal Kit was used to remove the rRNA from the total RNA. The Tru Seq Stranded Total RNA Library Prep Kit was used to preprocess the RNA and construct the sequencing library. The BioAnalyzer2100 instrument was used to control and quantify the library. According to the Illumina sequencing instructions, the 10 pM library was denatured into single-stranded DNA, which were captured by Illumina flowcell and amplified into clusters *in situ*. One hundred and fifty cycle sequencing was carried out on the Illumina HiSeq sequencer in double-terminal mode.

CircRNA sequencing data analysis

The circRNAs were sequenced by Illumina Hi Seq4000 sequencer, and the annotation reference multiple change (fold change, FC) and P value of the identified circRNAs were screened by the circBase database and circ2Traits. FC ≥ 2.0 (P < 0.05) was selected as the threshold for screening differential circRNAs.

Detection and analysis of LC-MS metabolomics

The non-target metabolic group of monocytes was detected by the Ultra-high Performance Liquid Chromatography-quadrupole Time-of-flight Mass Spectrometry (UHPLC-TOF-MS) (AB)/Q-Exactive Focus (Thermo)/Xevo G2-XS (Waters) detection platform. The acetonitrile (B)-water (0.1% formic acid) (A) mobile phase system was used, the analysis time was 30 min, the column temperature was 25 °C, the flow rate was 0.4 mL/min, the post-column split ratio was 2 μ L, the injection volume was 5 μ L, and the Ultraviolet (UV) detection wavelength was 286 nm.

In the positive ion mode of electrospray, the mass

scanning range was 70–1,000, the capillary voltage was 4,000 V, the atomization gas pressure was 40 psi, the drying gas speed was 10 L/min, the drying gas temperature was 350 °C, the fragment voltage was 160 V, and the reference calibration solution was selected for real-time mass correction. The experimental data were processed by Qualitative Analysis software. Before measuring the sample, the tuning liquid was used to calibrate the quality axis.

Statistical analysis

The original data are converted into. mzXML format by Proteo Wizard, and peak alignment, retention time correction, and peak area extraction were then carried out by XCMS software. The structure of metabolites was identified by accurate mass number matching (<25 ppm) and secondary spectrum matching, and the local database was searched. After Pareto-scaling processing, the data were analyzed by multi-dimensional statistical analysis such as unsupervised principal component analysis (PCA), supervised partial least square discriminant analysis (PLS-DA), and orthogonal partial least square discriminant analysis (OPLS-DA). Two samples were tested by SPSS 24.0. the difference was statistically significant. Under the conditions of variable projection importance value (variable importance for the projection, VIP) >1 and P < 0.1, the mass-charge ratio was screened and the differential metabolites were searched. The possible differential metabolites were searched in the Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. The level of metabolite enrichment in each pathway was analyzed by the Fisher test, and the affected metabolic and signal transduction pathways were finally determined.

Results

Transcriptome sequencing to screen differentially-expressed circRNAs

The blank control group, estrogen treatment group, gonococcal disease group, and gonococcal disease + estrogen treatment group samples were sequenced, and the differentially-expressed circRNAs were analyzed by cluster analysis (Figure 1) and Wayne diagram analysis (Figure 2). In addition, we also analyzed the results of K-means cluster diagram (Figure S1), and Self-Organizing Map (SOM) cluster (Figure S2) of differentially-expressed circRNAs among the groups. Further analysis of the differentially-




Figure 1 Differential circRNA cluster map, clustered according to the \log_{10} (TPM +1) value. Red indicates high expression of circRNA and blue indicates low expression of circRNA. Control1–3 is the blank control group; E2 1–3 is the estrogen treatment group; N g1–3 is the gonococcal disease group; and E2 Ng1–3 is the gonococcal disease + estrogen treatment group. CircRNA, circular RNA; TPM, transcripts per kilobase of exon model per million mapped reads.




Figure 2 CircRNA differential expression. Wayne diagram among different treatment groups, in which A represents blank control group; B represents estrogen treatment group; C represents gonococcal disease group; D represents gonococcal disease + estrogen treatment group. circRNA, circular RNA.

expressed circRNAs between the *Neisseria gonorrhoeae* disease group and the gonococcal disease + estrogen treatment group (Table S1) showed that after adding estrogen to the gonococcal infection model, there was up-regulated expression of 111 circRNAs expression, and down-regulated expression of 124 circRNAs (Figure 3A). Gene Ontology (GO) analysis showed that the differentially expressed circRNAs were mainly concentrated in metabolism-related and protein binding-related pathways (Figure 3B).

Screening differentially-expressed metabolites by LC-MS

The blank control group, estrogen treatment group, gonococcal disease group and gonococcal disease + estrogen treatment group samples were detected by LC-MS, and




Figure 3 CircRNA differential expression. Volcano map (A) and differential gene enrichment analysis map (B) between the *Neisseria gonorrhoeae* disease group and the gonococcal disease + estrogen treatment group. CircRNA, circular RNA; GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.




Figure 4 The PCA of all samples could be divided into scattered points: the abscissa PC [1] and ordinate PC [2] in the negative ion model result map (A) and the positive ion model result map (B) represent the scores of the first and second principal components, respectively. The color and shape of the scatter represent the experimental grouping of the sample, and the sample is basically within 95% confidence interval. A represents the blank control group; B represents the estrogen treatment group; C represents the gonococcal disease group; and D represents the gonococcal disease + estrogen treatment group. PCA, principal component analysis; PC, principal component.

the PCA dispersion points of all samples are shown in *Figure 4*. Further analysis of the differentially-expressed metabolites of the *Neisseria gonorrhoeae* disease group and the gonococcal disease + estrogen treatment group showed 70 differentially-expressed metabolites (*Table S2*). For the volcano map of these 68 differentially expressed metabolites, the displacement test results of the PCA dispersion plot and OPLS-DA model are shown in *Figure 5*, showing the detection results of differential metabolites in the negative

and positive ion modes, respectively.

In addition, the GO (*Table S3*) and KEGG (*Table S4*) databases were used to analyze the differential metabolites of each treatment group, which showed that the pathway mainly focused on the metabolism of various acids. The Metabolite Mapping statistical results of different metabolites among the various treatment groups showed that the addition of estrogen to the *Neisseria gonorrhoeae* model could lead to the abnormal expression of multiple




Figure 5 The difference volcano map of the metabolites of *Neisseria gonorrhoeae* and *Neisseria gonorrhoeae* estrogen groups. The PCA dispersion point map and the replacement test results of OPLS-DA model: (A) and (B) represent the difference volcano map of the negative ion and positive ion models, respectively. (C) and (D) represent the PCA dispersion point diagram of the negative ion and positive ion models, respectively, in which the abscissa PC [1] and the ordinate PC [2] represent the scores of the first and second principal components, respectively, and the color and shape of the scatter represent the experimental grouping of the sample. The sample is basically within 95% confidence interval, where C represents the gonococcal disease group and D represents the gonococcal disease + estrogen treatment group. (E) and (F) represent the permutation test results of the OPLS-DA model of negative and positive ion models, respectively. The abscissa represents the permutation retention degree of the permutation test (in proportion to the order of Y variables of the original model; the point where the permutation retention is equal to 1 is the R^2Y and Q^2 values of the original model), the ordinate represents the value of R^2Y or Q^2 , and the green dot represents the R^2Y value obtained by the permutation test. The blue square dot represents the Q^2 value obtained by the permutation test, and the two dotted lines represent the regression lines of R^2Y and Q^2 values, respectively. Q^2 , fraction of the total variation of the X block (PCA) or the Y block (PLS) that can be predicted by each component. R^2Y , fraction of the total variation of the Y block that can be explained by each component. VIP, variable importance for the projection; PCA, principal component analysis; OPLS-DA, orthogonal partial least squares discriminant analysis; PC, principal component; PLS, partial least square.

kinds of circRNAs and metabolites, and that there might be an interaction between these circRNAs and metabolites.

Analysis of the relationship between circRNAs and metabolites

In order to further clarify the relationship between circRNAs and metabolites, we analyzed the network relationship between the detection results of differential metabolites in the negative and positive ion modes and differential circRNA, respectively. The first 10 metabolites and circRNAs were significantly related to each other as follows: circology 0024520, circology 0024520, circology 0061793, excercination 0061793, and 4-methylpiperidine-4-methylpiperidine-dodecadienoate/novel_circ_0012178 (Table Slim 0056959-Acetone oxime/novel_circ_0012178; Adifoline/novel_circ_0012178; CARBETAPENTANE/novel_circ_0054387; CARBETAPENTANE/novel_circ_0056959; deoxy-PF1140/mmu_circ_0000397; and Methyl (2Ether 6Z). Among these, CARBETAPENTANE/novel_circ_0054387 and CARBETAPENTANE/novel_circ_0056959 were positively correlated, while the remaining metabolites and circRNAs were negatively correlated.

Discussion

In this study, transcriptome sequencing and metabonomics were applied to study the effects of estrogen on differentially-expressed circRNA and metabolites in the monocytes of mice infected with *Neisseria gonorrhoeae*. An estrogen-induced circRNA program was affected by the expression of cell cycle-related genes. The results showed that following the addition of estrogen to the gonococcal infection model, the expression of circRNAs was up-regulated and the expression of circRNAs was down-regulated. In the metabolic group, it was found that after the addition of estrogen, the expression of nine metabolites was down-regulated, and 61 metabolites were up-regulated. Based on the network interaction analysis of differentially-expressed circRNAs and differentially-expressed metabolites, it was found that the first 10 metabolites and circRNAs were significantly related to each other. Among them, CARBETAPENTANE/novel_circ_0054387 and CARBETAPENTANE/novel_circ_0056959 were positively correlated, while the remaining metabolites and circRNAs were negatively correlated. The results of this study are helpful in providing new research ideas and indicators for

female asymptomatic infection.

Previous studies have shown that estrogen can inhibit the chemotaxis of monocytes in mice with *Neisseria gonorrhoeae* infection, reduce the number of granulocytes in reproductive tract secretion, and inhibit inflammation to a certain extent (1,4). Estrogen not only inhibits the non-specific cellular immunity of neutrophils, but also inhibits local cellular and humoral immunity. Studies have shown that estrogen can promote the adhesion and colonization of *Candida albicans* in VK2/E6E7 cells by binding to estrogen receptor α and estrogen receptor β to regulate a series of downstream signaling pathways (13-15). Some studies have reported that although there is no significant difference in the prevalence of vulvovaginal candidiasis between women who are taking oral contraceptives and those who are not, the detection rate of vaginal *Candida albicans* is positively correlated with the content of estrogen in contraceptives (16). These results demonstrate that estrogen can enhance the adhesion and invasiveness of *Candida albicans* (15,17). Estrogen exerts anti-inflammatory effects, including the inhibition of pro-inflammatory gene transcription and cytokine production, as well as in several disease models such as autoimmunity, atherosclerosis, arthritis, inflammatory intestinal diseases, asthma, and influenza (18,19). In this study, it was found that following the addition of estrogen, the differentially-expressed circRNAs in monocytes were mainly concentrated in metabolism-related and protein binding-related pathways, which may suggest that estrogen affects cell metabolism and adhesion by regulating circRNAs.

The characteristics of circRNA molecules, such as tissue specificity, disease specificity, time sequence specificity, and high stability, reflect their important potential as a biomarker of clinical disease, as well as their roles in anti-infective immunity and inflammation. Regarding influenza A virus (IAV) infection, researchers previously established a mouse model of IAV infection and obtained 12 differentially-expressed circRNAs using bioinformatics software in the lung tissues of the IAV-infected mice (20,21). The results showed that 12 circRNA target genes played a role in the biological process, cell composition, and molecular function, and affected antigen processing and presentation, Tol receptor, retinoic acid-induced gene I-like receptor and myocardial function, as well as other related signaling pathways. Therefore, the researchers speculated that circRNA might participate in the IAV infection process via host immune regulation. CircRNAs is involved in the regulation of a variety of inflammatory responses. In




Figure 6 ROC analysis of top 10 significantly related circRNA and metabolites, show that $AUC = 1$. When $AUC > 0.5$, the result is more reliable, if AUC is closer to 1. This means the differentially-expressed circRNAs and metabolites regulated by estrogen are significant reliable. circRNA, circular RNA; ROC, receiver operating characteristics; AUC , area under the curve.

the preliminary research work, some researchers found that compared with healthy groups, there is a differential expression of circRNAs in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (22,23). The expression of circRNAs is both up-regulated and partly down-regulated; however, whether it is up- or down-regulated will affect the occurrence and development of SLE.

In this study, the interaction between differentially-expressed circRNAs and differential metabolites was also analyzed, and the regulatory network diagram was drawn. ROC analysis of top 10 significantly related circRNA and metabolites shows that $AUC = 1$. When $AUC > 0.5$, the result is more reliable, if AUC is closer to 1. This means the differentially-expressed circRNAs and metabolites regulated by estrogen are significant reliable. (Figure 6) Among the top 10 significant relationships between the circRNAs and differential metabolites selected, including *1,2-Epoxybutane/novel_circ_0024520*; *1,2-Epoxybutane/novel_circ_0061793*; *2-Imino-4-methylpiperidine/novel_circ_0012178*; *2-Imino-4-methylpiperidine/novel_circ_0056959*; *Acetone oxime/novel_circ_0012178*; *Adifoline/novel_circ_0012178*; *CARBETAPENTANE/novel_circ_0054387*; *CARBETAPENTANE/novel_circ_0056959*; *deoxy-PF1140/mmu_circ_0000397*; and *Methyl (2E,6Z)-dodecadienoate/novel_circ_0012178*. Among them, *CARBETAPENTANE/novel_circ_0054387* and *CARBETAPENTANE/novel_circ_0056959* while the remaining metabolites and circRNAs were negatively correlated. Metabolomics is an emerging omics

that enables comprehensive analysis of metabolites in biological samples is defined as metabolomics technology, and apply in many areas, such as, disease diagnosis, pharmaceutical research and development, nutrition and food science, toxicology, environmental science, botany. At this stage, it has limitations that metabolomics' databases are not sourced universal and shared. More and more scientific laboratories and organizations have set metabolomics standard documents, which means, the former limitations will be very likely conquered in the future. In the future, we will design further verification tests based on these corresponding relationships and correlations, clarify their regulatory functions, study the relationship between pathogens and hosts, and further explore the interaction between estrogen, circRNAs, and metabolites. This research is hugely important to the screening of anti-infection biomarkers as well as the study of asymptomatic infection of female mucosa.

Conclusions

In the *Neisseria gonorrhoeae* infection model, we found that the expression of circRNAs was up-regulated and the expression of circRNAs was down-regulated after adding estrogen. In the metabolic group, following the addition of estrogen, the expression of nine metabolites was down-regulated, while that of 61 metabolites was up-regulated. Moreover, through network interaction analysis

of the differentially-expressed circRNA and differentially-expressed metabolites, a series of interaction networks between metabolites and circRNAs were identified. In this study, estrogen-regulated differentially-expressed circRNAs and metabolites were screened by high-throughput sequencing, which was helpful in providing new research ideas and indicators for female asymptomatic infection.

Acknowledgments

Funding: This research was supported by grants from Natural Science Foundation of Guangzhou city of China (202002030106), Natural Science Foundation of Guangdong Province of China (2021A1515011218), National Natural Science Foundation of China (81872532), and Major Clinical Project of Affiliated Hospital of Guangdong Medical University (11002kpgyf20180012).

Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-3127/rc>

Data Sharing Statement: Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-3127/dss>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-3127/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Nair S, Sachdeva G. Estrogen matters in metastasis. *Steroids* 2018;138:108-16.
- Kovács K, Vásárhelyi B, Gyarmati B, et al. Estrogen metabolism during pregnancy. *Orv Hetil* 2019;160:1007-14.
- Hamilton KJ, Hewitt SC, Arao Y, et al. Estrogen Hormone Biology. *Curr Top Dev Biol* 2017;125:109-46.
- Raterman EL, Jerse AE. Female Mouse Model of *Neisseria gonorrhoeae* Infection. *Methods Mol Biol* 2019;1997:413-29.
- Edwards JL. *Neisseria gonorrhoeae* survival during primary human cervical epithelial cell infection requires nitric oxide and is augmented by progesterone. *Infect Immun* 2010;78:1202-13.
- Doufène K, Basile I, Lebrun A, et al. Vegetable oil-based hybrid microparticles as a green and biocompatible system for subcutaneous drug delivery. *Int J Pharm* 2021;592:120070.
- Wan Q, Deng Y, Huang Y, et al. Synthesis and Antitumor Evaluation of Novel Hybrids of Phenylsulfonylfuroxan and Estradiol Derivatives. *ChemistryOpen* 2019;9:176-82.
- Cipolletti M, Leone S, Bartoloni S, et al. Real-time measurement of E2: ER α transcriptional activity in living cells. *J Cell Physiol* 2020;235:6697-710.
- Rice PA, Shafer WM, Ram S, et al. *Neisseria gonorrhoeae*: Drug Resistance, Mouse Models, and Vaccine Development. *Annu Rev Microbiol* 2017;71:665-86.
- Zhao Q, Liu J, Deng H, et al. Targeting Mitochondria-located circRNA SCAR Alleviates NASH via Reducing mROS Output. *Cell* 2020;183:76-93.e22.
- Verduci L, Strano S, Yarden Y, et al. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. *Mol Oncol* 2019;13:669-80.
- Zang J, Lu D, Xu A. The interaction of circRNAs and RNA binding proteins: An important part of circRNA maintenance and function. *J Neurosci Res* 2020;98:87-97.
- Africander D, Louw R, Verhoog N, et al. Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. *Contraception* 2011;84:423-35.
- Youn H, Hong K, Yoo JW, et al. ICAM-1 expression in vaginal cells as a potential biomarker for inflammatory response. *Biomarkers* 2008;13:257-69.
- Arroyo-Mendoza M, Peraza K, Olson J, et al. Effect of testosterone and estrogen supplementation on the

- resistance to systemic *Candida albicans* infection in mice. *Heliyon* 2020;6:e04437.
16. Hall RA. Dressed to impress: impact of environmental adaptation on the *Candida albicans* cell wall. *Mol Microbiol* 2015;97:7-17.
 17. Luan T, Liu X, Mao P, et al. The Role of 17 β -Estrogen in *Candida albicans* Adhesion on Human Vaginal Epithelial Cells via FAK Phosphorylation. *Mycopathologia* 2020;185:425-38.
 18. Salinas-Muñoz L, Campos-Fernández R, Mercader E, et al. Estrogen Receptor-Alpha (ESR1) Governs the Lower Female Reproductive Tract Vulnerability to *Candida albicans*. *Front Immunol* 2018;9:1033.
 19. Wang L, Wang C, Mei H, et al. Combination of Estrogen and Immunosuppressive Agents to Establish a Mouse Model of Candidiasis with Concurrent Oral and Vaginal Mucosal Infection. *Mycopathologia* 2016;181:29-39.
 20. Liu Z, Guo Y, Zhao L, et al. Analysis of the circRNAs expression profile in mouse lung with H7N9 influenza A virus infection. *Genomics* 2021;113:716-27.
 21. Awan FM, Yang BB, Naz A, et al. The emerging role and significance of circular RNAs in viral infections and antiviral immune responses: possible implication as therapeutic agents. *RNA Biol* 2021;18:1-15.
 22. Luo Q, Li X, Fu B, et al. Expression profile and diagnostic value of circRNAs in peripheral blood from patients with systemic lupus erythematosus. *Mol Med Rep* 2021;23:1.
 23. Lodde V, Murgia G, Simula ER, et al. Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases. *Biomolecules* 2020;10:1044.
- (English Language Editor: A. Kassem)

Cite this article as: Cai G, Long J, Yang H, Xie J, Zou R, Zheng C, Chen X, Liu S, Chen R. The role of estrogen in circular RNA and metabolomics in a *Neisseria gonorrhoeae* infection model. *Ann Transl Med* 2022;10(18):999. doi: 10.21037/atm-22-3127




Figure S1 The K-means cluster diagram was used to cluster with $\log_2(\text{ratio})$ and the relative expression level of circRNA. The gray lines in each subgraph represent a line chart of the relative expression of circRNAs in a cluster under different experimental conditions. The blue lines represent the line chart of the average relative expression of all circRNAs in this cluster under different experimental conditions. Red line for reference; online for up-regulation; offline for down-regulation. The x-axis represents the experimental conditions and the y-axis represents the relative expression.




Figure S2 The SOM cluster diagram was plotted for cluster analysis according to the relative expression level of circRNAs and \log_2 (ratio). The gray lines in each subgraph represent a line chart of the relative expression of circRNAs in a cluster under different experimental conditions. The blue lines represent the line chart of the average relative expression of all circRNAs in this cluster under different experimental conditions. Red line for reference; online for up-regulation; offline for down-regulation. The x-axis represents the experimental conditions and the y-axis represents the relative expression. SOM, self-organizing feature map.

Table S1 differential expression of circRNA between gonococcal disease group and gonococcal disease + estrogen treatment group (|log₂FoldChange|> 1)

ID	log ₂ FoldChange	P value	Up/down
novel_circ_0053247	1.005	0.006	Up
novel_circ_0006039	1.024	0.011	Up
mmu_circ_0001067	1.033	0.012	Up
novel_circ_0007025	1.045	0.006	Up
novel_circ_0004284	1.087	0.008	Up
novel_circ_0015562	1.094	0.007	Up
novel_circ_0005831	1.123	0.006	Up
novel_circ_0011180	1.173	0.003	Up
novel_circ_0014946	1.183	0.004	Up
novel_circ_0009247	1.444	<0.001	Up
novel_circ_0010828	1.543	<0.001	Up
novel_circ_0004698	1.692	<0.001	Up
novel_circ_0022197	2.74	<0.001	Up
novel_circ_0022275	-4.042	<0.001	Down
novel_circ_0062043	-1.545	<0.001	Down
novel_circ_0030437	-1.467	<0.001	Down
novel_circ_0031952	-1.46	<0.001	Down
novel_circ_0014804	-1.332	0.001	Down
novel_circ_0053832	-1.163	0.002	Down
novel_circ_0007381	-1.147	0.003	Down
novel_circ_0011509	-1.114	0.007	Down
novel_circ_0031938	-1.105	0.003	Down
novel_circ_0025670	-1.085	0.006	Down
novel_circ_0004337	-1.072	0.009	Down
novel_circ_0035892	-1.063	0.007	Down
novel_circ_0049155	-1.046	0.005	Down
novel_circ_0049475	-1.028	0.005	Down

Table S2 differentially expressed metabolites between gonococcal disease group and gonococcal disease + estrogen treatment group ($|\log_2\text{FoldChange}|>1$)

ID	P value	$\log_2\text{FoldChange}$	NEG/POS	Up/down	MS name
764	0.018	-2.935	NEG	Down	
765	0.038	-1.499	NEG	Down	
724	0.033	-1.337	NEG	Down	
2071	0.006	1.005	NEG	Up	N-(3,5-Dichlorophenyl)succinimide
2087	0.036	1.03	NEG	Up	
16	0.034	1.076	NEG	Up	Xanthine
1148	0.022	1.124	NEG	Up	3,4,5-trihydroxy-6-[2-hydroxy-4-(3,5,6,7-tetrahydroxy-4-oxo-3,4-dihydro-2H-1-benzopyran-2-yl)phenoxy]oxane-2-carboxylic acid
2134	0.006	1.203	NEG	Up	
2092	0.017	1.254	NEG	Up	N-(3,5-Dichlorophenyl)succinimide
2091	0.003	1.64	NEG	Up	
1496	0.003	1.79	NEG	Up	
1466	0.001	1.95	NEG	Up	
2089	0.013	2.124	NEG	Up	
1149	0.018	2.508	NEG	Up	Irisxanthone
1147	0.035	2.549	NEG	Up	
1180	0.015	3.286	NEG	Up	
1455	0.04	7.241	NEG	Up	
2647	0.013	8.12	NEG	Up	
1768	0.048	-1.838	POS	Down	
2921	<0.001	-1.365	POS	Down	N,N'-Dimethylurea
2408	0.046	-1.229	POS	Down	
2619	0.016	-1.066	POS	Down	
817	0.001	-1.063	POS	Down	Violaceinic acid
2396	0.033	-1.058	POS	Down	
2890	0.044	1.017	POS	Up	
1373	0.001	1.037	POS	Up	
2895	0.002	1.044	POS	Up	
2636	0.031	1.072	POS	Up	
1338	0.031	1.096	POS	Up	Jacareubin
1677	0.028	1.1	POS	Up	2-Sulfotrehalose
3370	0.019	1.118	POS	Up	4-Fluorophenol
1913	0.038	1.131	POS	Up	3-[3,5-dihydroxy-4-(sulfooxy)benzoyloxy]-4,5-dihydroxybenzoic acid
1915	0.012	1.135	POS	Up	
3938	0.003	1.151	POS	Up	
1588	0.012	1.237	POS	Up	Irisxanthone
1744	<0.001	1.245	POS	Up	Deltamethrin

Table S2 (continued)

Table S2 (continued)

ID	P value	log ₂ FoldChange	NEG/POS	Up/down	MS name
3079	0.015	1.36	POS	Up	
1586	0.009	1.363	POS	Up	
1157	0.031	1.447	POS	Up	3,4,5-trihydroxy-6-(4-methoxy-1-benzofuran-5-carboxyloxy)oxane-2-carboxylic acid
1911	0.022	1.462	POS	Up	Propionyladenylate
1374	0.002	1.477	POS	Up	
1342	0.032	1.514	POS	Up	
745	0.041	1.526	POS	Up	
1341	0.012	1.531	POS	Up	
1589	0.028	1.593	POS	Up	
1627	0.044	1.625	POS	Up	
1158	0.017	1.632	POS	Up	[2,6-dihydroxy-4-({[2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}carbonyl)phenyl]oxidanesulfonic acid
1740	0.021	1.722	POS	Up	
1678	0.04	1.762	POS	Up	
3950	0.024	1.856	POS	Up	
2543	0.007	1.91	POS	Up	
1735	<0.001	1.967	POS	Up	
2542	0.035	2.07	POS	Up	
2763	0.037	2.09	POS	Up	
1676	0.025	2.183	POS	Up	
1592	0.007	2.201	POS	Up	Loquatoside
1409	0.04	2.239	POS	Up	
1376	0.003	2.301	POS	Up	
1448	0.035	2.409	POS	Up	
1391	0.005	2.503	POS	Up	dTDP-4-dimethylamino-4,6-dideoxy-5-C-methyl-L-mannose
1414	0.039	2.509	POS	Up	
1378	0.008	2.549	POS	Up	
1388	0.038	2.611	POS	Up	
1375	0.023	3.07	POS	Up	3,4,5-trihydroxy-6-{{[3-(6-hydroxy-7-methoxy-2H-1,3-benzodioxol-5-yl)prop-2-enyl]oxy}oxane-2-carboxylic acid
1415	0.006	3.618	POS	Up	Auranofin
2603	0.037	4.238	POS	Up	N-Acetyl-D-glucosamine 6-phosphate
1397	0.006	4.36	POS	Up	
1380	0.001	4.47	POS	Up	2-[(3-{4-[(6-carboxy-3,4,5-trihydroxyoxan-2-yl)oxy]-3-methoxyphenyl}prop-2-enyl)oxy]-3-hydroxybutanedioic acid
2752	0.046	6.524	POS	Up	
2597	0.004	7.044	POS	Up	

NEG, negative ion mode; POS, positive ion mode; MS, mass spectrometry.

Table S3 Statistical table of differential metabolite enrichment pathways between gonococcal disease group and gonococcal disease + estrogen treatment group

NEG/POS	Comparison	Pathway	Hits Cpd	P value	FDR
NEG	Neisseria gonorrhoeae-blank	Purine metabolism	Xanthine cpd:C00385	0.048	1
NEG	Neisseria gonorrhoeae estrogen-blank	Taurine and hypotaurine metabolism	Taurine cpd:C00245	0.028	1
NEG	Neisseria gonorrhoeae estrogen-blank	Biosynthesis of unsaturated fatty acids	Oleic acid cpd:C00712	0.14	1
NEG	Neisseria gonorrhoeae estrogen-blank	Fatty acid biosynthesis	Oleic acid cpd:C00712	0.143	1
NEG	Neisseria gonorrhoeae estrogen-blank	Primary bile acid biosynthesis	Taurine cpd:C00245	0.152	1
NEG	Neisseria gonorrhoeae estrogen-blank	Purine metabolism	Xanthine cpd:C00385	0.218	1
NEG	Estrogen-Neisseria gonorrhoeae estrogen	Biosynthesis of unsaturated fatty acids	Oleic acid cpd:C00712	0.058	1
NEG	Estrogen-Neisseria gonorrhoeae estrogen	Fatty acid biosynthesis	Oleic acid cpd:C00712	0.06	1
NEG	Neisseria gonorrhoeae estrogen-gonococcus	Purine metabolism	Xanthine cpd:C00385	0.048	1
POS	Neisseria gonorrhoeae-blank	Glutathione metabolism	Glutathione cpd:C00051; L-Glutamic acid cpd:C00025	0.002	0.156
POS	Neisseria gonorrhoeae-blank	D-Glutamine and D-glutamate metabolism	L-Glutamic acid cpd:C00025	0.014	0.576
POS	Neisseria gonorrhoeae-blank	Nitrogen metabolism	L-Glutamic acid cpd:C00025	0.025	0.689
POS	Neisseria gonorrhoeae-blank	Histidine metabolism	L-Glutamic acid cpd:C00025	0.042	0.772
POS	Neisseria gonorrhoeae-blank	Butanoate metabolism	L-Glutamic acid cpd:C00025	0.061	0.772
POS	Neisseria gonorrhoeae-blank	Alanine, aspartate and glutamate metabolism	L-Glutamic acid cpd:C00025	0.066	0.772
POS	Neisseria gonorrhoeae-blank	Porphyrin and chlorophyll metabolism	L-Glutamic acid cpd:C00025	0.074	0.772
POS	Neisseria gonorrhoeae-blank	Glycerophospholipid metabolism	Choline cpd:C00114	0.082	0.772
POS	Neisseria gonorrhoeae-blank	Glycine, serine and threonine metabolism	Choline cpd:C00114	0.085	0.772
POS	Neisseria gonorrhoeae-blank	Arginine and proline metabolism	L-Glutamic acid cpd:C00025	0.119	0.973
POS	Neisseria gonorrhoeae-blank	Aminoacyl-tRNA biosynthesis	L-Glutamic acid cpd:C00025	0.181	1
POS	Neisseria gonorrhoeae estrogen-blank	Arginine and proline metabolism	L-Glutamic acid cpd:C00025; L-Proline cpd:C00148; Creatine cpd:C00300	0.001	0.074
POS	Neisseria gonorrhoeae estrogen-blank	Aminoacyl-tRNA biosynthesis	L-Tryptophan cpd:C00078; L-Proline cpd:C00148; L-Glutamic acid cpd:C00025	0.003	0.138
POS	Neisseria gonorrhoeae estrogen-blank	Glutathione metabolism	Glutathione cpd:C00051; L-Glutamic acid cpd:C00025	0.006	0.176
POS	Neisseria gonorrhoeae estrogen-blank	Glycine, serine and threonine metabolism	Choline cpd:C00114; Creatine cpd:C00300	0.009	0.186

Table S3 (continued)

Table S3 (continued)

NEG/POS	Comparison	Pathway	Hits Cpd	P value	FDR
POS	Neisseria gonorrhoeae estrogen-blank	D-Glutamine and D-glutamate metabolism	L-Glutamic acid cpd:C00025	0.024	0.402
POS	Neisseria gonorrhoeae estrogen-blank	Nitrogen metabolism	L-Glutamic acid cpd:C00025	0.044	0.597
POS	Neisseria gonorrhoeae estrogen-blank	Histidine metabolism	L-Glutamic acid cpd:C00025	0.072	0.843
POS	Neisseria gonorrhoeae estrogen-blank	Butanoate metabolism	L-Glutamic acid cpd:C00025	0.104	1
POS	Neisseria gonorrhoeae estrogen-blank	Alanine, aspartate and glutamate metabolism	L-Glutamic acid cpd:C00025	0.113	1
POS	Neisseria gonorrhoeae estrogen-blank	Porphyrin and chlorophyll metabolism	L-Glutamic acid cpd:C00025	0.126	1
POS	Neisseria gonorrhoeae estrogen-blank	Glycerophospholipid metabolism	Choline cpd:C00114	0.139	1
POS	Neisseria gonorrhoeae estrogen-blank	Tryptophan metabolism	L-Tryptophan cpd:C00078	0.182	1
POS	Estrogen-Neisseria gonorrhoeae estrogen	Aminoacyl-tRNA biosynthesis	L-Phenylalanine cpd:C00079; L-Proline cpd:C00148; L-Glutamic acid cpd:C00025	0	0.035
POS	Estrogen-Neisseria gonorrhoeae estrogen	Arginine and proline metabolism	L-Glutamic acid cpd:C00025; L-Proline cpd:C00148	0.005	0.223
POS	Estrogen-Neisseria gonorrhoeae estrogen	Phenylalanine, tyrosine and tryptophan biosynthesis	L-Phenylalanine cpd:C00079	0.011	0.288
POS	Estrogen-Neisseria gonorrhoeae estrogen	D-Glutamine and D-glutamate metabolism	L-Glutamic acid cpd:C00025	0.014	0.288
POS	Estrogen-Neisseria gonorrhoeae estrogen	Nitrogen metabolism	L-Glutamic acid cpd:C00025	0.025	0.413
POS	Estrogen-Neisseria gonorrhoeae estrogen	Phenylalanine metabolism	L-Phenylalanine cpd:C00079	0.031	0.42
POS	Estrogen-Neisseria gonorrhoeae estrogen	Histidine metabolism	L-Glutamic acid cpd:C00025	0.042	0.489
POS	Estrogen-Neisseria gonorrhoeae estrogen	Butanoate metabolism	L-Glutamic acid cpd:C00025	0.061	0.553
POS	Estrogen-Neisseria gonorrhoeae estrogen	Alanine, aspartate and glutamate metabolism	L-Glutamic acid cpd:C00025	0.066	0.553
POS	Estrogen-Neisseria gonorrhoeae estrogen	Glutathione metabolism	L-Glutamic acid cpd:C00025	0.071	0.553
POS	Estrogen-Neisseria gonorrhoeae estrogen	Porphyrin and chlorophyll metabolism	L-Glutamic acid cpd:C00025	0.074	0.553

NEG, negative ion mode; POS, positive ion mode; FDR, false discovery rate.

Table S4 Metabolite Mapping statistics of different metabolites among treatment groups

NEG/POS	Comparison	HMDB	KEGG	Query	Match
NEG	Neisseria gonorrhoeae-blank	HMDB0000292	C00385	Xanthine	Xanthine
NEG	Estrogen-blank	HMDB0000847	C01601	Pelargonate	Pelargonic acid
NEG	Neisseria gonorrhoeae estrogen-blank	HMDB0000251	C00245	Taurine	Taurine
NEG	Neisseria gonorrhoeae estrogen-blank	HMDB0000744	C00711	Malic acid	Malic acid
NEG	Neisseria gonorrhoeae estrogen-blank	HMDB0000292	C00385	Xanthine	Xanthine
NEG	Neisseria gonorrhoeae estrogen-blank	HMDB0000847	C01601	Pelargonate	Pelargonic acid
NEG	Neisseria gonorrhoeae estrogen-blank	HMDB0000207	C00712	Oleic acid	Oleic acid
NEG	Estrogen-Neisseria gonorrhoeae estrogen	HMDB0000744	C00711	Malic acid	Malic acid
NEG	Estrogen-Neisseria gonorrhoeae estrogen	HMDB0000207	C00712	Oleic acid	Oleic acid
NEG	Neisseria gonorrhoeae estrogen-gonococcus	HMDB0000292	C00385	Xanthine	Xanthine
POS	Neisseria gonorrhoeae-blank	HMDB0000097	C00114	Choline	Choline
POS	Neisseria gonorrhoeae-blank	HMDB0000148	C00025	Glutamate	L-Glutamic acid
POS	Neisseria gonorrhoeae-blank	HMDB0000125	C00051	Glutathione	Glutathione
POS	Neisseria gonorrhoeae-blank	HMDB0033244	C14214	Di-n-butyl phthalate	Dibutyl phthalate
POS	Neisseria gonorrhoeae-blank	HMDB0035228		Theaspiron A	Theaspiron A
POS	Neisseria gonorrhoeae-blank	HMDB0034495		6,10,14-Trimethyl-5,9,13- pentadecatrien-2-one	6,10,14-Trimethyl-5,9,13- pentadecatrien-2-one
POS	Estrogen-blank	HMDB0034146	C13846	Stearamide	Octadecanamide
POS	Neisseria gonorrhoeae estrogen-blank	HMDB0000097	C00114	Choline	Choline
POS	Neisseria gonorrhoeae estrogen-blank	HMDB0000162	C00148	Proline	L-Proline
POS	Neisseria gonorrhoeae estrogen-blank	HMDB0000148	C00025	Glutamate	L-Glutamic acid
POS	Neisseria gonorrhoeae estrogen-blank	HMDB0000929	C00078	Tryptophan	L-Tryptophan
POS	Neisseria gonorrhoeae estrogen-blank	HMDB0000125	C00051	Glutathione	Glutathione
POS	Neisseria gonorrhoeae estrogen-blank	HMDB0000805	C02237	(R)-(+)-2-Pyrrolidone-5- carboxylic acid	Pyrrolidonecarboxylic acid
POS	Neisseria gonorrhoeae estrogen-blank	HMDB0000064	C00300	Creatine	Creatine

Table S4 (continued)

Table S4 (continued)

NEG/POS	Comparison	HMDB	KEGG	Query	Match
POS	Estrogen-Neisseria gonorrhoeae estrogen	HMDB0031641		Pyrrolidine	Pyrrolidine
POS	Estrogen-Neisseria gonorrhoeae estrogen	HMDB0000162	C00148	Proline	L-Proline
POS	Estrogen-Neisseria gonorrhoeae estrogen	HMDB0000159	C00079	Phenylalanine	L-Phenylalanine
POS	Estrogen-Neisseria gonorrhoeae estrogen	HMDB0000148	C00025	Glutamate	L-Glutamic acid
POS	Estrogen-Neisseria gonorrhoeae estrogen	HMDB0000805	C02237	(R)-(+)-2-Pyrrolidone-5-carboxylic acid	Pyrrolidonecarboxylic acid

NEG, negative ion mode; POS, positive ion mode; KEGG, Kyoto Encyclopedia of Genes and Genomes.